Free Trial
NASDAQ:BJDX

Bluejay Diagnostics 11/7/2024 Earnings Report

Bluejay Diagnostics logo
$1.56 -0.13 (-7.69%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$1.58 +0.02 (+1.60%)
As of 06:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bluejay Diagnostics EPS Results

Actual EPS
-$8.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bluejay Diagnostics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bluejay Diagnostics Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Bluejay Diagnostics Earnings Headlines

Bluejay Diagnostics Inc BJDX
Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
See More Bluejay Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bluejay Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bluejay Diagnostics and other key companies, straight to your email.

About Bluejay Diagnostics

Bluejay Diagnostics (NASDAQ:BJDX), a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

View Bluejay Diagnostics Profile

More Earnings Resources from MarketBeat